Announcement PDF ASX Announcement AGM Chair address and CEO presentation Melbourne, Australia; 14 November 2025: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today provides a copy of the Chair’s address and CEO’s presentation, which will be presented at the Annual General Meeting (AGM) of Starpharma Holdings Limited, starting at 2:00 pm (Melbourne time) today. About Starpharma Starpharma ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications. Starpharma’s portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn. Investor & Media Relations Gabriella Hold gaby@thecapitalnetwork.com.au Starpharma Holdings Limited Cheryl Maley, Chief Executive Officer Justin Cahill, Chief Financial and Operations Officer and Company Secretary +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford VIC 3067 Disclosure This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas. Forward-Looking Statements This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product. 2 Starpharma Holdings Limited Annual General Meeting 14 November 2025 Chair’s address to shareholders Good afternoon, fellow shareholders. Welcome to Starpharma’s 2025 Annual General Meeting. On behalf of the Board of Directors, thank you for joining us today and for your continued support of Starpharma. This past year has been a turning point for the company. We leveraged the work of the past, sharpened our strategic focus and delivered on key milestones that position Starpharma for long- term growth and value creation. These achievements demonstrate strong execution across our three key strategic pillars of maximising the DEP® platform, accelerating innovation, and building long-term sustainability. Our progress has been marked by disciplined execution, bold decisions, and a relentless drive to unlock the full potential of Starpharma’s cutting-edge proprietary dendrimer technology. Strategic partnerships: Driving validation and commercial expansion The most significant development this year has been the momentum in our partnership efforts. The execution of two major agreements - with Genentech, a member of the Roche Group, and Radiopharm Theranostics - signal a new era for Starpharma. These partnerships are not simply commercial transactions, they represent powerful external validations of our DEP® platform and scientific expertise. The Genentech agreement alone brought an upfront payment of USD $5.5 million, with potential milestone payments of up to USD $564 million and tiered royalties on global net sales. The Radiopharm Theranostics collaboration marks our first formal partnership in radiopharmaceuticals, opening new avenues for innovation and revenue. These achievements are the result of extensive groundwork, strategic reviews, and market engagement. They demonstrate that leading global companies see the same potential in Starpharma that we do, and they are willing to invest in our vision. The Radiopharm Theranostics agreement also represents our first Star Navigator program to progress into a formal research collaboration. Star Navigator, launched earlier this year, enables partners across all stages of drug development to access and test Starpharma’s dendrimer technology for hands-on innovation. This initiative has already generated strong interest in our DEP® platform and supports our goal of forging more strategic partnerships that expand our reach and accelerate the development of dendrimer-based therapies. And it makes commercial sense for drug development organisations to consider our platform given how many potential drugs fail because of toxicology or solubility issues, areas that we can address, let alone allowing far greater penetration of the drug into tumours. In addition to these key partnerships, we continue to actively explore and engage additional global collaborative opportunities to extend the reach of our DEP® platform. 3 Operational excellence: Advancing innovation and clinical progress This year also marked significant progress in advancing our pipeline of internal DEP® assets. A key priority for Starpharma is expediting our radiotheranostics program into clinical development. Having completed extensive pre-clinical work this year, our DEP® HER2 radiotheranostics program is now progressing towards a first-in-human clinical trial. We aim to commence the trial in 2026, enrolling patients with HER2-positive cancers, an area of significant unmet clinical need. We have also continued to focus on maximising the value of Starpharma’s lead clinical-stage assets: DEP® SN38 and DEP® cabazitaxel. We were proud to see the results for DEP® SN38 published in the Journal of Clinical Oncology in August 2025 - a significant validation of both the program and the underlying DEP® platform. We have also continued to support Petalion Therapeutics and our global Viraleze™ and VivaGel® BV partners, and have made additional investments in Starpharma’s internal drug discovery capabilities to advance and strengthen our development pipeline. Building shareholder value: The road ahead Looking forward, our strategy is clear and focused on: • Securing strategic partnerships • Advancing DEP® radiopharmaceuticals into clinical trials • Increasing revenues from licensing and product sales • Operational excellence We commenced FY26 with strong momentum, a robust balance sheet, and multiple opportunities for value creation. Our leadership team, led by CEO Cheryl Maley, brings deep expertise and fosters a high-performance culture that gives us great confidence in our ability to execute. Your board and management team are collaborating effectively to achieve our strategic objectives. To our valued shareholders: you are integral to Starpharma’s journey. We appreciate your trust and patience. This has enabled us to pursue ambitious goals and navigate the complexities of biotech innovation. We believe we are building something truly special - a company with unique technology, the people, and the vision to deliver enduring value and global impact. The journey ahead is filled with opportunity. With every partnership, clinical milestone, and strategic decision, we are working to restore and grow shareholder value. Above all, our purpose remains clear: to translate our innovative dendrimer technology into treatments that improve outcomes and quality of life for patients worldwide. On behalf of the Board, I sincerely thank you for your continued support as we pursue a future of enduring impact, sustainable growth, and long-term success. Thank you, Rob Thomas, AO Chair Delivering meaningful patient outcomes with advanced dendrimer technology Annual General Meeting | 14 November 2025 CEO, Cheryl Maley ASX : SPL US OTC : SPHRY Disclaimer and forward-looking statements This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors. 2 Our year in review Reflecting on a year of important progress 3 Ticker ASX:SPL US OTC: SPHRY Share Price ~A$0.45 (~USD$0.29) Market Capitalisation ~A$186M Total ordinary shares on issue 418M GICS classification Pharmaceuticals, Biotechnology & Life Sciences 52-week range $0.082 - $0.445 Average daily volume ~980K Cash Balance (30 Sep 2025) A$14.3M (excludes the $8.5M payment from Genentech received on 22 October 2025) 4 Share price Allianz SE 11.8% Robmar Investments Pty Ltd 7.1% ICM Investment Management Ltd 6.4% ^Annual Report 2025 Substantial shareholders^ Market position Driving value through innovation Our strategy Optimising shareholder returns through three key focus areas 5 Maximising DEP® platform value Demonstrating DEP® benefits by developing novel, high- value assets 01 Building strategic partnerships Creating licensing opportunities for DEP® and commercialisation 02 Building long-term sustainability Increasing revenue, strengthening IP, and fostering a high-performance culture 03 2025 Overview Key achievements and key actions to advance SPL in 2026 6 GOALS ACHIEVED ONGOING Maximise DEP® platform value Build long-term sustainability • License DEP® clinical asset/s • Advance radio assets & build comprehensive data set • Identify new modalities & novel assets for development • Radiopharmaceutical collaboration • GNE License Agreement • Advanced Petalion • Launched Star Navigator • FDA advice, extensive outreach, global support • Optimised radio asset, pre- clinical program almost complete • Progress existing partners – Genentech, Petalion, and MSD • Convert new partnership opportunities • Sustainable income streams • VivaGel® BV EU Licence & webstore • Strengthen IP position • AI integration • Deliver to partner plans • Confirm next steps of existing collaborations • Engaging new collaborations • Increased Viraleze online sales, new VivaGel® BV partners (ME & SEA) • IP strategy review • Launched AI project • License DEP® clinical asset/s • Partnering for Radio Assets • New modality feasibility • Increase Viraleze & VivaGel® BV sales • Maximise IP value • Use AI to increase R&D efficiency • High performance culture Build strategic partnerships Our pipeline Unlocking value through novel asset development, strategic partnerships, and product sales 7 Internal DEP® Pipeline Product Target indication Research Pre- clinical Phase I Phase II Phase III Strategy DEP® SN38 Ovarian and colorectal License/co- develop – ovarian, colorectal DEP® cabazitaxel Prostate and gastro- oesophageal License – prostate, ovarian DEP® docetaxel Pancreatic and other cancers DEP® HER2 radiodiagnostic Diagnostic Optimise and accelerate to clinical DEP® HER2 radiotherapeutic Solid cancers Advance to clinical Early-stage projects Various Clinical results reported Clinical results reported Partnered DEP® Programs SPL7013 Products on Market Clinical results reported 8 Steph Associate Director, Clinical Development 18 years at Starpharma Suvir Associate Director, Business Development 8 years at Starpharma Key feedback on DEP® SN38 pathway for platinum-resistant ovarian cancer (PROC): • PROC - significant unmet need. • “505(b)(2)” pathway confirmed. • Potential for Fast Track designation and accelerated approval. Positive FDA engagement DEP® SN38 clinical study results peer-reviewed and published in the highly regarded Journal of Clinical Oncology. Journal publication Significant internal and external resources dedicated to advance licensing opportunities with prospective partners. Leveraging key opinion leaders and clinical experts to strengthen commercialisation. External expertise Business development team participation in key industry conferences to engage with prospective partners and showcase the value of Starpharma’s DEP® platform. Conference participation DEP® clinical assets Maximising opportunities for potential out-licensing 9 10 Michael Principal Research Scientist 25 years at Starpharma 11 48h ex vivo biodistribution Molecular Weight (kDa) 10 25-75 150 Tumour Retention Low High Tumour Uptake (time) Fast Slow Blood Clearance Fast Slow Kidney Accumulation High Low 1 0 5 10 15 %ID/g G2 G3 G4 mAb G5 mAb fragment Targeted dendrimers 0 1 0 2 0 3 0 4 0 %ID/g G2 G3 G4 mAb G5 mAb fragment Targeted dendrimers Kidney Clearance Tumour Targeting HER2+ BT474 tumour Blood dendrimers G2 G3 G4 G5 Ab fragment mAb Dendrimers Strategic opportunity in radiopharmaceuticals Optimising the DEP® platform to enhance radiotherapies • Key driver in aggressive breast & gastric cancers • Targeting & inhibiting HER2 slows tumour growth & improves treatment outcomes Why HER2 • Combined HER2+ breast & gastric cancer market: ~USD $12.4B in 2025, growing to ~USD $15.3B by 2035 • New treatments expanding the market to HER2-low patients Market size • Progression, resistance, and/or toxicities from other HER2 therapies (e.g., mAb, ADCs, TKIs) Current treatment challenges • To develop a novel mode of action with the potential to treat tumours resistant or refractory to current HER2 therapies, offering improved patient outcomes • Potential for DEP® to provide significant efficacy and toxicity improvements Opportunity DEP® HER2 radio therapy that offers: • Rapid tumour accumulation • Prolonged tumour retention • Rapid blood clearance • Avoids kidney clearance and accumulation SPL’s target product profile DEP® HER2 radiotherapy program Advancing from preclinical to clinical in 2026 Our strategy Optimising shareholder returns through three key focus areas 13 Maximising DEP® platform value 01 Building strategic partnerships 02 Building long-term sustainability 03 14 Amanda Senior Director, Business Development & Project Lead for our New Seeds program 1.5 years at Starpharma Tony Vice President, Business Development 12 years at Starpharma Our strategic partnerships Expanding opportunities for commercialisation 15 Exclusive License Agreement • Limited targets, multi- product • Deal value: up to USD $564M plus royalties Joint Venture • Single asset focus • USD $25M investment by Medicxi • SPL holds 22.5% equity in Petalion Research and Option Agreement • Single asset focus • Deal value up to ~AUD $91M plus royalties Recent media coverage and commentary Positioning DEP® as a next-gen oncology delivery platform beyond biologics 16 17 Sammi Senior Research Scientist & Project Manager for the Genentech program Nearly 14 years at Starpharma Medicxi strategic partnership Encouraging progress and feedback 18 “I am really pleased that the collaboration between Petalion and SPL has been very positive, with both teams working closely and constructively toward shared goals. A great deal of work has already been done, thanks to the strong commitment and energy from everyone involved. The work at Petalion continues to progress in line with the plan and timelines set out at the inception of the company in 2024. The team remains focused and coordinated, ensuring that activities and experiments stay on track to deliver the project milestones. Further updates will be provided in due course as the programme advances.” – Mehdi Shahidi MD CEO, Petalion Therapeutics October 2025 Star Navigator Expanding access to Starpharma’s proprietary dendrimers through collaborative drug development and innovation 19 Star Navigator Expanding access to Starpharma’s proprietary dendrimers through collaborative drug development and innovation 20 • Launched early 2025 • Flexible partnership frameworks • Designed to streamline access • Experiment yourself or engage our experts Our strategy Optimising shareholder returns through three key focus areas 21 Maximising DEP® platform value 01 Building strategic partnerships 02 Building long-term sustainability 03 22 Laura Regulatory Affairs Manager 11 years at Starpharma Launching UK webstore in 2026 ITROM launch in Middle East showing encouraging uptake so far Supporting Aspen’s growth in AU/NZ Ongoing process for securing new partnerships Viraleze and VivaGel® BV Increasing revenues through distribution partnerships and online sales Viraleze • Registered in more than 35 jurisdictions*, including in Europe, the UK, and Asia. • Priority markets: UK, Germany, and Middle East (E&N). VivaGel® BV • Registered in 40+ jurisdictions, including in the UK, Europe, Southeast Asia, Australia and New Zealand. • Priority markets: Australia and New Zealand (Aspen), Middle East and North Africa (ITROM), Europe and the UK. 23 *Viraleze is not approved for use or supply in Australia. Ongoing digital marketing campaigns Increasing access via multiple online channels FY26 online sales (webstore & Amazon) to date: up nearly 60% 150+ customer reviews (4.9/5-star rating) E&N launch in Middle East showing encouraging uptake so far 24 Gareth Analytical and Data Science Manager & Project Lead for Starpharma’s AI program Nearly 5 years at Starpharma Sammi Senior Research Scientist Nearly 14 years at Starpharma AI at Starpharma Leveraging our strengths and data to accelerate the discovery and preclinical phase of drug development 25 Number of compounds 5,000 – 20,000 250 5 1 Basic research Drug discovery Preclinical research Clinical research Approved drug Combining nearly 30 years of expertise in dendrimer drug development with sophisticated AI tools to accelerate research, drug discovery, and preclinical development. 26 Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Our DEP® strategy Leveraging multiple pathways to maximise shareholder returns DEP Platform Strategic partnerships Novel asset development 27 Radiotheranostics, ADCs, combination therapies, non- oncology molecules (revenue from asset license & commercialisation) Multinational, private equity, biotechnology (revenue from platform license - development to commercialisation, R&D services) Our strategy & outlook Focusing on strategic execution and revenue generation 28 1) Maximise DEP® platform value • Progressing radiotheranostic program to the clinic • Securing license/collaboration for a DEP® asset to commercialise • Converting early discovery to development program 2) Building strategic partnerships • Progressing and expanding current partner programs • Securing new partnered programs 3) Building long-term sustainability • Securing new VivaGel® BV EU / ROW partner(s) • Increasing revenue from licensing and product sales Three focused strategic imperatives and anticipated catalysts Financial position Building long-term sustainability 29 Multiple revenue streams Annual result FY25 FY24 Revenue $4.9M $1.7M^ Loss $10.0M $14.7M^ ^excluding the one-time $6.6M Mundipharma settlement payment $14.3M cash at 30 September 2025 (excluding the $8.5M upfront licensing receipt from Genentech on 22 October 2025) Increasing revenues, with multiple revenue streams:  Licensing & milestone payments  Marketed product sales: VivaGel® BV & Viraleze  R&D income from services provided to partners Leadership team Driving innovation with global expertise 30 Cheryl Maley Chief Executive Officer & Managing Director Justin Cahill Chief Financial & Operations Officer & Company Secretary Dr Jeremy Paull Chief Scientific & Regulatory Officer Dr Tony Eglezos VP, Business Development Dr Brian Kelly Director, Manufacture & Laboratory Operations Dr Richard Hufton Director, Discovery Research Graham Heery Director, Translational Science & CMC Miranda Sowden Director, People & Culture Sindy Smith Commun- ications & Investor Relations Manager Board of directors Driving innovation with global expertise 31 Rob Thomas AO Independent non- executive director; Chair, Board Cheryl Maley Chief Executive Officer & Managing Director David McIntyre Independent Non- executive director; Chair, Audit & Risk Committee Lynda Cheng Independent non-executive director; Chair, Remuneration & Nomination Committee Dr Jeff Davies Independent non- executive director Dr Russell Basser Independent non- executive director Thank you. Investor Relations Investor.Relations@Starpharma.com www.starpharma.com Corporate Office 4 – 6 Southampton Crescent Abbotsford, Victoria 3067 Australia ASX : SPL US OTC : SPHRY